ArticleHematology, transfusion and cell therapy2026
Fresh (Non-cryopreserved) autologous stem cell transplantation in multiple myeloma: Faster engraftment and reduced hospitalization.
Article in Hematology, transfusion and cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCryopreserved autologous hematopoietic stem cell transplantation using dimethyl sulfoxide is standard in multiple myeloma but it is associated with infusion-related toxicity and high cost. This study aimed to evaluate the feasibility, safety, and outcomes of dimethyl sulfoxide-free, fresh (non-cryopreserved) autologous stem cell transplantation in multiple myeloma patients at a single tertiary center.
methodsA retrospective analysis was conducted in 40 multiple myeloma patients who underwent transplantation using freshly collected, non-cryopreserved peripheral blood stem cells between 2023 and 2025 at Dokuz Eylül University Hospital. Peripheral blood stem cells were infused within 72 h after collection without cryopreservation. Engraftment kinetics, toxicity, and length of hospital stay were assessed descriptively.
resultsAll patients achieved hematopoietic engraftment (100%). Median neutrophil and platelet engraftment occurred at nine (range: 6-14) and 11 days (range: 7-16), respectively and the median hospitalization was 13 days. No infusion-related adverse events or grade 3-4 mucositis were observed. This approach eliminated dimethyl sulfoxide-related toxicity, reduced cryopreservation-related resource utilization and associated procedural costs.
conclusionFresh, dimethyl sulfoxide-free autologous stem cell transplantation in multiple myeloma is a safe, effective, and cost-efficient alternative to cryopreserved transplantation. It provides rapid engraftment, reduced hospitalization, and improved patient comfort, representing a practical model for modern transplant centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.